首页 > 最新文献

Best Practice & Research in Clinical Rheumatology最新文献

英文 中文
Highlights of advancement in Rheumatoid Arthritis research and clinical practice 类风湿关节炎研究和临床实践的进展要点。
IF 4.5 2区 医学 Q1 RHEUMATOLOGY Pub Date : 2025-03-01 DOI: 10.1016/j.berh.2025.102040
Jing He , Ajesh Basantharan Maharaj
{"title":"Highlights of advancement in Rheumatoid Arthritis research and clinical practice","authors":"Jing He , Ajesh Basantharan Maharaj","doi":"10.1016/j.berh.2025.102040","DOIUrl":"10.1016/j.berh.2025.102040","url":null,"abstract":"","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"39 1","pages":"Article 102040"},"PeriodicalIF":4.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utility of polygenic risk scores to aid in the diagnosis of rheumatic diseases 多基因风险评分在风湿病诊断中的应用。
IF 4.5 2区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-12-01 DOI: 10.1016/j.berh.2024.101973
Lucía Santiago-Lamelas , Raquel Dos Santos-Sobrín , Ángel Carracedo , Patricia Castro-Santos , Roberto Díaz-Peña
Rheumatic diseases (RDs) are characterized by autoimmunity and autoinflammation and are recognized as complex due to the interplay of multiple genetic, environmental, and lifestyle factors in their pathogenesis. The rapid advancement of genome-wide association studies (GWASs) has enabled the identification of numerous single nucleotide polymorphisms (SNPs) associated with RD susceptibility. Based on these SNPs, polygenic risk scores (PRSs) have emerged as promising tools for quantifying genetic risk in this disease group. This chapter reviews the current status of PRSs in assessing the risk of RDs and discusses their potential to improve the accuracy of the diagnosis of these complex diseases through their ability to discriminate among different RDs. PRSs demonstrate a high discriminatory capacity for various RDs and show potential clinical utility. As GWASs continue to evolve, PRSs are expected to enable more precise risk stratification by integrating genetic, environmental, and lifestyle factors, thereby refining individual risk predictions and advancing disease management strategies.
风湿性疾病(RDs)以自身免疫和自身炎症为特征,其发病机制因多种遗传、环境和生活方式因素的相互作用而变得复杂。随着全基因组关联研究(GWAS)的迅速发展,人们发现了许多与 RD 易感性相关的单核苷酸多态性(SNPs)。基于这些 SNPs,多基因风险评分(PRSs)已成为量化该疾病群体遗传风险的有效工具。本章回顾了多基因风险评分在评估 RD 风险方面的现状,并讨论了多基因风险评分通过区分不同 RD 的能力来提高这些复杂疾病诊断准确性的潜力。PRS 对各种 RD 具有很高的鉴别能力,并显示出潜在的临床实用性。随着全球基因组研究的不断发展,PRSs有望通过整合遗传、环境和生活方式因素实现更精确的风险分层,从而完善个体风险预测并推进疾病管理策略。
{"title":"Utility of polygenic risk scores to aid in the diagnosis of rheumatic diseases","authors":"Lucía Santiago-Lamelas ,&nbsp;Raquel Dos Santos-Sobrín ,&nbsp;Ángel Carracedo ,&nbsp;Patricia Castro-Santos ,&nbsp;Roberto Díaz-Peña","doi":"10.1016/j.berh.2024.101973","DOIUrl":"10.1016/j.berh.2024.101973","url":null,"abstract":"<div><div><span>Rheumatic diseases (RDs) are characterized by autoimmunity and autoinflammation and are recognized as complex due to the interplay of multiple </span>genetic<span>, environmental, and lifestyle factors in their pathogenesis. The rapid advancement of genome-wide association studies (GWASs) has enabled the identification of numerous single nucleotide polymorphisms<span> (SNPs) associated with RD susceptibility. Based on these SNPs, polygenic risk scores (PRSs) have emerged as promising tools for quantifying genetic risk in this disease group. This chapter reviews the current status of PRSs in assessing the risk of RDs and discusses their potential to improve the accuracy of the diagnosis of these complex diseases through their ability to discriminate among different RDs. PRSs demonstrate a high discriminatory capacity for various RDs and show potential clinical utility. As GWASs continue to evolve, PRSs are expected to enable more precise risk stratification by integrating genetic, environmental, and lifestyle factors, thereby refining individual risk predictions and advancing disease management strategies.</span></span></div></div>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"38 4","pages":"Article 101973"},"PeriodicalIF":4.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141602126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetics of rheumatoid arthritis 类风湿性关节炎的遗传学。
IF 4.5 2区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-12-01 DOI: 10.1016/j.berh.2024.101968
Seema D. Sharma , Shek H. Leung , Sebastien Viatte
In the past four decades, a plethora of genetic association studies have been carried out in cohorts of patients with rheumatoid arthritis. These studies have highlighted key aspects of disease pathogenesis and suggested causal mechanisms. In this review, we discuss major advances in our understanding of the genetic architecture of rheumatoid arthritis susceptibility, severity and treatment response and explain how genetics supports current models of disease pathogenesis and outcome. We outline future research directions, like Mendelian randomisation, and present a number of potential avenues for clinical translation, including risk and outcome prediction, patient stratification into treatment response groups and pharmacological applications.
在过去的四十年中,针对类风湿关节炎患者群体开展了大量的遗传关联研究。这些研究强调了疾病发病机制的关键方面,并提出了致病机制。在这篇综述中,我们将讨论在了解类风湿性关节炎易感性、严重性和治疗反应的遗传结构方面取得的主要进展,并解释遗传学如何支持当前的疾病发病机制和结果模型。我们概述了未来的研究方向,如孟德尔随机化,并提出了一些潜在的临床转化途径,包括风险和结果预测、患者治疗反应分层和药理应用。
{"title":"Genetics of rheumatoid arthritis","authors":"Seema D. Sharma ,&nbsp;Shek H. Leung ,&nbsp;Sebastien Viatte","doi":"10.1016/j.berh.2024.101968","DOIUrl":"10.1016/j.berh.2024.101968","url":null,"abstract":"<div><div>In the past four decades, a plethora of genetic association studies have been carried out in cohorts of patients with rheumatoid arthritis. These studies have highlighted key aspects of disease pathogenesis and suggested causal mechanisms. In this review, we discuss major advances in our understanding of the genetic architecture of rheumatoid arthritis susceptibility, severity and treatment response and explain how genetics supports current models of disease pathogenesis and outcome. We outline future research directions, like Mendelian randomisation, and present a number of potential avenues for clinical translation, including risk and outcome prediction, patient stratification into treatment response groups and pharmacological applications.</div></div>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"38 4","pages":"Article 101968"},"PeriodicalIF":4.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insights into the genetic landscape of systemic sclerosis 洞察系统性硬化症的基因状况。
IF 4.5 2区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-12-01 DOI: 10.1016/j.berh.2024.101981
Ali El-Halwagi, Sandeep K. Agarwal
Systemic sclerosis (SSc) is a complex autoimmune disease that clinically manifests as progressive fibrosis of the skin and internal organs. Autoimmunity and endothelial dysfunction play important roles in the development of SSc but the causes of SSc remain unknown. Accumulating evidence, first from familial aggregation studies and subsequently from candidate gene association studies and genome wide association studies underscore the crucial contributions of genetics to the development of SSc. The identification of polymorphisms in the HLA region as well as non-HLA loci is important for understanding the risks of developing SSc but can also provide important pathogenic insight in SSc. While not translating into clinic practice yet, understanding the genetic landscape of SSc will hopefully assist in the diagnosis and management of patients with and/or at risk of developing SSc in the future. Herein we review the studies that investigate genetic risks of SSc susceptibility.
系统性硬化症(SSc)是一种复杂的自身免疫性疾病,临床表现为皮肤和内脏器官的进行性纤维化。自身免疫和内皮功能障碍在系统性硬化症的发病过程中起着重要作用,但系统性硬化症的病因仍然不明。越来越多的证据,首先是来自家族聚集研究,随后是候选基因关联研究和全基因组关联研究,都强调了遗传学对 SSc 发病的关键作用。鉴定 HLA 区域和非 HLA 位点的多态性对于了解 SSc 的发病风险非常重要,同时也能为 SSc 的致病提供重要启示。虽然目前还不能转化为临床实践,但了解 SSc 的遗传情况将有助于今后对 SSc 患者和/或有患病风险的患者进行诊断和管理。在此,我们回顾了有关 SSc 易感性遗传风险的研究。
{"title":"Insights into the genetic landscape of systemic sclerosis","authors":"Ali El-Halwagi,&nbsp;Sandeep K. Agarwal","doi":"10.1016/j.berh.2024.101981","DOIUrl":"10.1016/j.berh.2024.101981","url":null,"abstract":"<div><div>Systemic sclerosis (SSc) is a complex autoimmune disease that clinically manifests as progressive fibrosis of the skin and internal organs. Autoimmunity and endothelial dysfunction play important roles in the development of SSc but the causes of SSc remain unknown. Accumulating evidence, first from familial aggregation studies and subsequently from candidate gene association studies and genome wide association studies underscore the crucial contributions of genetics to the development of SSc. The identification of polymorphisms in the HLA region as well as non-HLA loci is important for understanding the risks of developing SSc but can also provide important pathogenic insight in SSc. While not translating into clinic practice yet, understanding the genetic landscape of SSc will hopefully assist in the diagnosis and management of patients with and/or at risk of developing SSc in the future. Herein we review the studies that investigate genetic risks of SSc susceptibility.</div></div>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"38 4","pages":"Article 101981"},"PeriodicalIF":4.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141789824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preface to genomics of rheumatic disease 风湿病基因组学》序言。
IF 4.5 2区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-12-01 DOI: 10.1016/j.berh.2024.102005
Anne Barton, Proton Rahman
{"title":"Preface to genomics of rheumatic disease","authors":"Anne Barton,&nbsp;Proton Rahman","doi":"10.1016/j.berh.2024.102005","DOIUrl":"10.1016/j.berh.2024.102005","url":null,"abstract":"","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"38 4","pages":"Article 102005"},"PeriodicalIF":4.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacogenetics of therapies in rheumatoid arthritis: An update 类风湿性关节炎的药物遗传学疗法:最新进展。
IF 4.5 2区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-12-01 DOI: 10.1016/j.berh.2024.101974
Mohamed H. Babiker-Mohamed , Sambhawana Bhandari , Prabha Ranganathan
Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory arthritis. Despite many treatment advances, achieving remission or low-disease activity in RA remains challenging, often requiring trial and error approaches with numerous medications. Precision medicine, particularly pharmacogenomics, explores how genetic factors influence drug response in individual patients, and incorporates such factors to develop personalized treatments for individual patients. Genetic variations in drug-metabolizing enzymes, transporters, and targets may contribute to inter-individual differences in drug efficacy and toxicity. Advancements in molecular sequencing have allowed rapid identification of such variants, including single nucleotide polymorphisms (SNPs). This review highlights recent major findings in the pharmacogenetics of therapies in RA, focusing on key genes and SNPs to provide insights into current trends and developments in this field.
类风湿性关节炎(RA)是一种全身性自身免疫性炎症性关节炎。尽管在治疗方面取得了许多进展,但要实现类风湿关节炎的缓解或低疾病活动度仍然具有挑战性,往往需要使用多种药物进行反复试验。精准医学,尤其是药物基因组学,探索遗传因素如何影响个体患者对药物的反应,并结合这些因素为个体患者开发个性化治疗方法。药物代谢酶、转运体和靶点的基因变异可能导致药物疗效和毒性的个体差异。分子测序技术的进步使得包括单核苷酸多态性(SNPs)在内的此类变异得以快速鉴定。这篇综述重点介绍了最近在RA药物遗传学治疗方面的主要发现,重点关注关键基因和SNPs,以便深入了解该领域当前的趋势和发展。
{"title":"Pharmacogenetics of therapies in rheumatoid arthritis: An update","authors":"Mohamed H. Babiker-Mohamed ,&nbsp;Sambhawana Bhandari ,&nbsp;Prabha Ranganathan","doi":"10.1016/j.berh.2024.101974","DOIUrl":"10.1016/j.berh.2024.101974","url":null,"abstract":"<div><div>Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory arthritis. Despite many treatment advances, achieving remission or low-disease activity in RA remains challenging, often requiring trial and error approaches with numerous medications. Precision medicine, particularly pharmacogenomics, explores how genetic factors influence drug response in individual patients, and incorporates such factors to develop personalized treatments for individual patients. Genetic variations in drug-metabolizing enzymes, transporters, and targets may contribute to inter-individual differences in drug efficacy and toxicity. Advancements in molecular sequencing have allowed rapid identification of such variants, including single nucleotide polymorphisms (SNPs). This review highlights recent major findings in the pharmacogenetics of therapies in RA, focusing on key genes and SNPs to provide insights into current trends and developments in this field.</div></div>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"38 4","pages":"Article 101974"},"PeriodicalIF":4.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141735577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of Mendelian randomization to assess the causal status of modifiable exposures for rheumatic diseases 使用孟德尔随机法评估风湿病可改变暴露的因果关系。
IF 4.5 2区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-12-01 DOI: 10.1016/j.berh.2024.101967
Sizheng Steven Zhao , Stephen Burgess
The explosion in Mendelian randomization (MR) publications is hard to ignore and shows no signs of slowing. Clinician readers, who may not be familiar with jargon-ridden methods, are expected to discern the good from the many low-quality studies that make overconfident claims of causality or stretch the plausibility of what MR can investigate. We aim to equip readers with foundational concepts, contextualized using examples in rheumatology, to appraise the many MR papers that are or will appear in their journals. We highlight the importance of assessing whether exposures are under plausibly specific genetic influence, whether the hypothesized causal pathways make biological sense, and whether results stand up to replication and use of control outcomes. Quality of research can vary substantially using MR as with any design, and all methods have inherent limitations. MR studies have provided and can still contribute valuable insights in the context of evidence triangulation.
孟德尔随机化(Mendelian randomization,MR)出版物的爆炸式增长令人难以忽视,而且没有放缓的迹象。临床读者可能对术语繁多的方法并不熟悉,他们需要从众多低质量的研究中辨别优劣,这些低质量的研究过于自信地声称存在因果关系,或者夸大了孟德尔随机研究的可信度。我们的目标是通过风湿病学中的实例为读者提供基本概念,使他们能够对期刊中正在或将要发表的众多磁共振论文进行评估。我们强调了评估暴露是否受到可信的特定遗传影响、假设的因果途径是否具有生物学意义以及结果是否经得起复制和使用对照结果的重要性。与任何设计一样,使用磁共振技术进行的研究质量可能会有很大差异,而且所有方法都有其固有的局限性。在证据三角测量的背景下,磁共振研究已经并仍能提供有价值的见解。
{"title":"Use of Mendelian randomization to assess the causal status of modifiable exposures for rheumatic diseases","authors":"Sizheng Steven Zhao ,&nbsp;Stephen Burgess","doi":"10.1016/j.berh.2024.101967","DOIUrl":"10.1016/j.berh.2024.101967","url":null,"abstract":"<div><div>The explosion in Mendelian randomization (MR) publications is hard to ignore and shows no signs of slowing. Clinician readers, who may not be familiar with jargon-ridden methods, are expected to discern the good from the many low-quality studies that make overconfident claims of causality or stretch the plausibility of what MR can investigate. We aim to equip readers with foundational concepts, contextualized using examples in rheumatology, to appraise the many MR papers that are or will appear in their journals. We highlight the importance of assessing whether exposures are under plausibly specific genetic influence, whether the hypothesized causal pathways make biological sense, and whether results stand up to replication and use of control outcomes. Quality of research can vary substantially using MR as with any design, and all methods have inherent limitations. MR studies have provided and can still contribute valuable insights in the context of evidence triangulation.</div></div>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"38 4","pages":"Article 101967"},"PeriodicalIF":4.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7616521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the contribution of genetics on the clinical manifestations of systemic lupus erythematosus 探索遗传学对系统性红斑狼疮临床表现的影响。
IF 4.5 2区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-12-01 DOI: 10.1016/j.berh.2024.101971
Ruth D. Rodríguez , Marta E. Alarcón-Riquelme
Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by diverse clinical manifestations affecting multiple organs and systems. The understanding of genetic factors underlying the various manifestations of SLE has evolved considerably in recent years. This review provides an overview of the genetic implications in some of the most prevalent manifestations of SLE, including renal involvement, neuropsychiatric, cutaneous, constitutional, musculoskeletal, and cardiovascular manifestations. We discuss the current state of knowledge regarding the genetic basis of these manifestations, highlighting key genetic variants and pathways implicated in their pathogenesis. Additionally, we explore the clinical implications of genetic findings, including their potential role in risk stratification, prognosis, and personalized treatment approaches for patients with SLE. Through a comprehensive examination of the genetic landscape of SLE manifestations, this review aims to provide insights into the underlying mechanisms driving disease heterogeneity and inform future research directions in this field.
系统性红斑狼疮(SLE)是一种复杂的自身免疫性疾病,其特点是临床表现多种多样,影响多个器官和系统。近年来,人们对系统性红斑狼疮各种表现的遗传因素的认识有了长足的进步。本综述概述了系统性红斑狼疮一些最常见表现的遗传影响,包括肾脏受累、神经精神、皮肤、体质、肌肉骨骼和心血管表现。我们讨论了有关这些表现的遗传基础的知识现状,强调了与这些表现的发病机制有关的关键遗传变异和途径。此外,我们还探讨了遗传发现的临床意义,包括它们在系统性红斑狼疮患者的风险分层、预后和个性化治疗方法中的潜在作用。本综述旨在通过对系统性红斑狼疮表现的遗传情况进行全面研究,深入了解驱动疾病异质性的潜在机制,并为该领域未来的研究方向提供参考。
{"title":"Exploring the contribution of genetics on the clinical manifestations of systemic lupus erythematosus","authors":"Ruth D. Rodríguez ,&nbsp;Marta E. Alarcón-Riquelme","doi":"10.1016/j.berh.2024.101971","DOIUrl":"10.1016/j.berh.2024.101971","url":null,"abstract":"<div><div>Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by diverse clinical manifestations affecting multiple organs and systems. The understanding of genetic factors underlying the various manifestations of SLE has evolved considerably in recent years. This review provides an overview of the genetic implications in some of the most prevalent manifestations of SLE, including renal involvement, neuropsychiatric, cutaneous, constitutional, musculoskeletal, and cardiovascular manifestations. We discuss the current state of knowledge regarding the genetic basis of these manifestations, highlighting key genetic variants and pathways implicated in their pathogenesis. Additionally, we explore the clinical implications of genetic findings, including their potential role in risk stratification, prognosis, and personalized treatment approaches for patients with SLE. Through a comprehensive examination of the genetic landscape of SLE manifestations, this review aims to provide insights into the underlying mechanisms driving disease heterogeneity and inform future research directions in this field.</div></div>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"38 4","pages":"Article 101971"},"PeriodicalIF":4.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A review of the advances in understanding the genetic basis of spondylarthritis and emerging clinical benefit 回顾在了解脊柱关节炎遗传基础方面取得的进展以及新出现的临床益处。
IF 4.5 2区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-12-01 DOI: 10.1016/j.berh.2024.101982
Michael Stadler , Sizheng Steven Zhao , John Bowes
Spondyloarthropathies (SpA), including ankylosing spondylitis (AS) and psoriatic arthritis (PsA), have been shown to have a substantial genetic predisposition based on heritability estimates derived from family studies and genome-wide association studies (GWAS). GWAS have uncovered numerous genetic loci associated with susceptibility to SpA, with significant associations to human leukocyte antigen (HLA) genes, which are major genetic risk factors for both AS and PsA. Specific loci differentiating PsA from cutaneous-only psoriasis have been identified, though these remain limited. Further research with larger sample sizes is necessary to identify more PsA-specific genetic markers. Current research focuses on translating these genetic insights into clinical applications. For example, polygenic risk scores are showing promise for the classification of disease risk and diagnosis and future research should focus on refining these risk assessment tools to improve clinical outcomes for individuals with SpA. Addressing these challenges will help integrate genetic testing into patients care and impact clinical practice.
脊柱关节病(Spondyloarthropathies,SpA),包括强直性脊柱炎(ankylosing spondylitis,AS)和银屑病关节炎(psoriatic arthritis,PsA),根据家族研究和全基因组关联研究(genome-wide association studies,GWAS)得出的遗传率估计值,已被证明有很大的遗传倾向。全基因组关联研究(GWAS)发现了许多与 SpA 易感性相关的基因位点,其中与人类白细胞抗原(HLA)基因有显著关联的位点是 AS 和 PsA 的主要遗传风险因素。目前已确定了区分 PsA 和单纯皮肤型银屑病的特定基因位点,但这些位点仍然有限。有必要进行样本量更大的进一步研究,以确定更多 PsA 特异性遗传标记。目前的研究重点是将这些遗传学见解转化为临床应用。例如,多基因风险评分显示了疾病风险分类和诊断的前景,未来的研究应侧重于完善这些风险评估工具,以改善 SpA 患者的临床疗效。应对这些挑战将有助于将基因检测纳入患者护理并影响临床实践。
{"title":"A review of the advances in understanding the genetic basis of spondylarthritis and emerging clinical benefit","authors":"Michael Stadler ,&nbsp;Sizheng Steven Zhao ,&nbsp;John Bowes","doi":"10.1016/j.berh.2024.101982","DOIUrl":"10.1016/j.berh.2024.101982","url":null,"abstract":"<div><div>Spondyloarthropathies (SpA), including ankylosing spondylitis (AS) and psoriatic arthritis (PsA), have been shown to have a substantial genetic predisposition based on heritability estimates derived from family studies and genome-wide association studies (GWAS). GWAS have uncovered numerous genetic loci associated with susceptibility to SpA, with significant associations to human leukocyte antigen (HLA) genes, which are major genetic risk factors for both AS and PsA. Specific loci differentiating PsA from cutaneous-only psoriasis have been identified, though these remain limited. Further research with larger sample sizes is necessary to identify more PsA-specific genetic markers. Current research focuses on translating these genetic insights into clinical applications. For example, polygenic risk scores are showing promise for the classification of disease risk and diagnosis and future research should focus on refining these risk assessment tools to improve clinical outcomes for individuals with SpA. Addressing these challenges will help integrate genetic testing into patients care and impact clinical practice.</div></div>","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"38 4","pages":"Article 101982"},"PeriodicalIF":4.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142121108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Explainable biology for improved therapies in precision medicine: AI is not enough 用可解释的生物学改进精准医疗的疗法:仅有人工智能是不够的
IF 4.5 2区 医学 Q1 RHEUMATOLOGY Pub Date : 2024-12-01 DOI: 10.1016/j.berh.2024.102006
I Jurisica
Technological advances and high-throughput bio-chemical assays are rapidly changing ways how we formulate and test biological hypotheses, and how we treat patients. Most complex diseases arise on a background of genetics, lifestyle and environment factors, and manifest themselves as a spectrum of symptoms. To fathom intricate biological processes and their changes from healthy to disease states, we need to systematically integrate and analyze multi-omics datasets, ontologies, and diverse annotations. Without proper management of such complex biological and clinical data, artificial intelligence (AI) algorithms alone cannot be effectively trained, validated, and successfully applied to provide trustworthy and patient-centric diagnosis, prognosis and treatment. Precision medicine requires to use multi-omics approaches effectively, and offers many opportunities for using AI, “big data” analytics, and integrative computational biology workflows.
Advances in optical and biochemical assay technologies including sequencing, mass spectrometry and imaging modalities have transformed research by empowering us to simultaneously view all genes expressed, identify proteome-wide changes, and assess interacting partners of each individual protein within a dynamically changing biological system, at an individual cell level. While such views are already having an impact on our understanding of healthy and disease conditions, it remains challenging to extract useful information comprehensively and systematically from individual studies, ensure that signal is separated from noise, develop models, and provide hypotheses for further research. Data remain incomplete and are often poorly connected using fragmented biological networks. In addition, statistical and machine learning models are developed at a cohort level and often not validated at the individual patient level.
Combining integrative computational biology and AI has the potential to improve understanding and treatment of diseases by identifying biomarkers and building explainable models characterizing individual patients. From systematic data analysis to more specific diagnostic, prognostic and predictive biomarkers, drug mechanism of action, and patient selection, such analyses influence multiple steps from prevention to disease characterization, and from prognosis to drug discovery. Data mining, machine learning, graph theory and advanced visualization may help identify diagnostic, prognostic and predictive biomarkers, and create causal models of disease. Intertwining computational prediction and modeling with biological experiments leads to faster, more biologically and clinically relevant discoveries.
However, computational analysis results and models are going to be only as accurate and useful as correct and comprehensive are the networks, ontologies and datasets used to build them. High quality, curated data portals provide the necessary foundation for translati
技术进步和高通量生化检测正在迅速改变我们提出和检验生物学假设的方式,以及我们治疗病人的方式。大多数复杂疾病都是在遗传、生活方式和环境因素的基础上产生的,并表现为一系列症状。为了弄清复杂的生物过程及其从健康状态到疾病状态的变化,我们需要系统地整合和分析多组学数据集、本体论和各种注释。如果不能妥善管理这些复杂的生物和临床数据,仅靠人工智能(AI)算法是无法进行有效训练、验证和成功应用的,也就无法提供值得信赖的、以患者为中心的诊断、预后和治疗。精准医疗要求有效使用多组学方法,这为使用人工智能、"大数据 "分析和整合计算生物学工作流程提供了许多机会。光学和生化检测技术(包括测序、质谱分析和成像模式)的进步改变了研究工作,使我们有能力在单个细胞水平上同时查看所有表达的基因,识别整个蛋白质组的变化,并评估动态变化的生物系统中每个蛋白质的相互作用伙伴。虽然这种视图已经对我们了解健康和疾病状况产生了影响,但要从单项研究中全面系统地提取有用信息、确保信号与噪声分离、建立模型并为进一步研究提供假设,仍然具有挑战性。数据仍然不完整,而且往往利用支离破碎的生物网络进行连接。此外,统计和机器学习模型是在队列水平上开发的,往往没有在患者个体水平上进行验证。将综合性计算生物学与人工智能相结合,有可能通过识别生物标志物和建立可解释的模型来描述个体患者的特征,从而提高对疾病的理解和治疗。从系统数据分析到更具体的诊断、预后和预测生物标志物、药物作用机制和患者选择,此类分析影响着从预防到疾病特征描述、从预后到药物发现的多个步骤。数据挖掘、机器学习、图论和高级可视化可帮助确定诊断、预后和预测生物标志物,并创建疾病的因果模型。将计算预测和建模与生物实验相结合,可以更快、更多地发现生物和临床相关性。然而,计算分析结果和模型的准确性和实用性取决于用于构建这些结果和模型的网络、本体和数据集的正确性和全面性。高质量、经过整理的数据门户网站为转化研究提供了必要的基础。它们有助于确定更好的生物标志物、新药和精准治疗,并能改善患者的治疗效果和生活质量。将计算预测和建模与生物实验有效地结合起来,可以更快地获得更有用的发现。
{"title":"Explainable biology for improved therapies in precision medicine: AI is not enough","authors":"I Jurisica","doi":"10.1016/j.berh.2024.102006","DOIUrl":"10.1016/j.berh.2024.102006","url":null,"abstract":"<div><div>Technological advances and high-throughput bio-chemical assays are rapidly changing ways how we formulate and test biological hypotheses, and how we treat patients. Most complex diseases arise on a background of genetics, lifestyle and environment factors, and manifest themselves as a spectrum of symptoms. To fathom intricate biological processes and their changes from healthy to disease states, we need to systematically integrate and analyze multi-omics datasets, ontologies, and diverse annotations. Without proper management of such complex biological and clinical data, artificial intelligence (AI) algorithms alone cannot be effectively trained, validated, and successfully applied to provide trustworthy and patient-centric diagnosis, prognosis and treatment. Precision medicine requires to use multi-omics approaches effectively, and offers many opportunities for using AI, “big data” analytics, and integrative computational biology workflows.</div><div>Advances in optical and biochemical assay technologies including sequencing, mass spectrometry and imaging modalities have transformed research by empowering us to simultaneously view all genes expressed, identify proteome-wide changes, and assess interacting partners of each individual protein within a dynamically changing biological system, at an individual cell level. While such views are already having an impact on our understanding of healthy and disease conditions, it remains challenging to extract useful information comprehensively and systematically from individual studies, ensure that signal is separated from noise, develop models, and provide hypotheses for further research. Data remain incomplete and are often poorly connected using fragmented biological networks. In addition, statistical and machine learning models are developed at a cohort level and often not validated at the individual patient level.</div><div>Combining integrative computational biology and AI has the potential to improve understanding and treatment of diseases by identifying biomarkers and building explainable models characterizing individual patients. From systematic data analysis to more specific diagnostic, prognostic and predictive biomarkers, drug mechanism of action, and patient selection, such analyses influence multiple steps from prevention to disease characterization, and from prognosis to drug discovery. Data mining, machine learning, graph theory and advanced visualization may help identify diagnostic, prognostic and predictive biomarkers, and create causal models of disease. Intertwining computational prediction and modeling with biological experiments leads to faster, more biologically and clinically relevant discoveries.</div><div>However, computational analysis results and models are going to be only as accurate and useful as correct and comprehensive are the networks, ontologies and datasets used to build them. High quality, curated data portals provide the necessary foundation for translati","PeriodicalId":50983,"journal":{"name":"Best Practice & Research in Clinical Rheumatology","volume":"38 4","pages":"Article 102006"},"PeriodicalIF":4.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Best Practice & Research in Clinical Rheumatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1